8 completed, 3 terminated, 1 recruiting. 11 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 8, Terminated 2, Recruiting 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Prelude Therapeutics Incorporated: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms PRT12396 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Recruiting | Prelude Therapeutics Incorporated | 100 | 2026-04-29 | 2026-10-01 |
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT3789, pembrolizumab - Advanced Solid Tumor, Esophageal Cancer | Phase 2 | Terminated | Prelude Therapeutics Incorporated | 6 | 2025-06-03 | 2026-02-02 |
| A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT7732 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 42 | 2024-11-04 | 2026-02-02 |
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies PRT2527, Zanubrutinib, Venetoclax - Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2023-09-12 | 2026-01-26 |
| PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation PRT3789, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Completed | Prelude Therapeutics Incorporated | 135 | 2023-05-02 | 2025-10-16 |
| A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors PRT3645 - Breast Cancer, Glioblastoma | Phase 1 | Completed | Prelude Therapeutics Incorporated | 22 | 2022-12-27 | 2024-07-01 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies PRT1419, Azacitidine, Venetoclax - Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 21 | 2022-03-22 | 2024-01-31 |
| A Study of PRT2527 in Participants With Advanced Solid Tumors PRT2527 - Sarcoma, Castrate Resistant Prostate Cancer | Phase 1 | Completed | Prelude Therapeutics Incorporated | 30 | 2022-02-14 | 2023-12-11 |
| A Study of PRT1419 in Patients With Advanced Solid Tumors PRT1419 - Sarcoma, Melanoma | Phase 1 | Completed | Prelude Therapeutics Incorporated | 26 | 2021-08-11 | 2023-03-15 |
| A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies PRT1419 - Multiple Myeloma, Acute Myeloid Leukemia | Phase 1 | Completed | Prelude Therapeutics Incorporated | 16 | 2020-09-28 | 2022-11-15 |
| A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas PRT811 - Advanced Solid Tumor, Recurrent Glioma | Phase 1 | Completed | Prelude Therapeutics Incorporated | 86 | 2019-11-06 | 2023-04-05 |
| A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies PRT543 - Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 | Completed | Prelude Therapeutics Incorporated | 232 | 2019-02-11 | 2023-03-28 |
Leukemia, Myeloid, Acute (4) · Breast Neoplasms (3) · Leukemia, Myelomonocytic, Chronic (3) · Lymphoma, Mantle-Cell (3) · Myelodysplastic Syndromes (3) · Neoplasm Metastasis (3) · Recurrence (3) · Sarcoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Hematologic Neoplasms (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Myeloproliferative Disorders (2)
venetoclax (2) · Azacitidine (1) · Docetaxel (1) · pembrolizumab (1) · zanubrutinib (1)
United States (12) · Spain (4) · Australia (3) · France (3) · Germany (2) · Singapore (2) · South Korea (2) · Canada (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · Switzerland (1) · United Kingdom (1)